Cerbios-Pharma and Xspray Microparticles have signed a letter of intent to develop a long term, mutually beneficial collaboration whereby Xspray will be the preferred technology provider and Cerbios will be the preferred manufacturer for the joint development of HPAI (High Potency Active Ingredients) products with unique characteristics.

The formulation and manufacturing abilities of Xspray's Rightsize technology offer the opportunity to improve drug substances through various strategies, enabling full control over particle design and production - simplifying drug formulation, extending delivery options and allowing the addition of innovative properties that truly benefit patients.
The Rightsize technology uses supercritical fluid as an antisolvent for controlled precipitation of an active pharmaceutical ingredient/drug substance.
Rightsize technology not only provides a superior process to traditional methods it can also be effectively scaled from discovery scale up to production volumes, making it an important breakthrough in the manufacture of pharmaceutical particles using supercritical fluid technology. One of the advantages of this technology is that the moderate temperatures used make it ideal for particle size reduction of thermo labile compounds.
The development phases will be provided by Xspray in Stockholm , while the cGMP production for clinical and/or commercial at Cerbios in Lugano.

"We are enthusiastic about this partnership with Xspray. Access to Rightsize technology will strengthen our API development and manufacturing competency for third parties", says Dr. Gabriel Haering, CEO of Cerbios. "Through the use of this innovative technology for HPAI at a first stage, Cerbios will be able to offer a unique capability, enabling the generation not only of particles having narrow Particle Size Distribution (PSD) but also different crystal forms and/or polymorphs up to the full control of particle design, including solid state form. In combination with other technologies available at Cerbios it will generate Intellectual Property that will definitely help our partners in their success."

"Xspray's Rightsize technology is a perfect complement to the considerable knowledge and extensive experience of Cerbios-Pharma in the field of manufacturing and handling of HPAI". Commented XSpray's CEO, Dr. Per Andersson. "We are very pleased with this collaboration. Cerbios has an excellent track record with over 30 years of experience in process development and manufacturing from early stage to commercial supply."